TY - JOUR
T1 - Not so EEZE
T2 - The 'EDHF' antagonist 14, 15 epoxyeicosa-5(Z)-enoic acid has vasodilator properties in mesenteric arteries
AU - Harrington, Louise S.
AU - Falck, J R
AU - Mitchell, Jane A.
PY - 2004/12/15
Y1 - 2004/12/15
N2 - P-450 metabolites, including the epoxyeicosatrienoic acids, are likely candidates for endothelial derived hyperpolarising factor (EDHF). In the present study, we confirm that the stable analogue 11-nonyloxyundec-8(Z)-enoic acid is a vasodilator of murine vessels. However, we also show that the 'epoxyeicosatrienoic acid receptor' antagonist 14,15 EEZE similarly dilates murine vessels contracted with U46619, prostaglandin F 2α or methoxamine, but not with endothelin-1 or potassium. We suggest that 14,15 EEZE is a partial agonist for the epoxyeicosatrienoic acids/EDHF receptor. These results illustrate an important pharmacological property of this antagonists, which is being increasingly used to study the nature of EDHF.
AB - P-450 metabolites, including the epoxyeicosatrienoic acids, are likely candidates for endothelial derived hyperpolarising factor (EDHF). In the present study, we confirm that the stable analogue 11-nonyloxyundec-8(Z)-enoic acid is a vasodilator of murine vessels. However, we also show that the 'epoxyeicosatrienoic acid receptor' antagonist 14,15 EEZE similarly dilates murine vessels contracted with U46619, prostaglandin F 2α or methoxamine, but not with endothelin-1 or potassium. We suggest that 14,15 EEZE is a partial agonist for the epoxyeicosatrienoic acids/EDHF receptor. These results illustrate an important pharmacological property of this antagonists, which is being increasingly used to study the nature of EDHF.
KW - 14,15 EEZE
KW - EDHF (Endothelial derived hyperpolarising factor)
KW - Hyperpolarisation
KW - Mesenteric artery
KW - U46619
KW - mouse
UR - http://www.scopus.com/inward/record.url?scp=9944228231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9944228231&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2004.09.062
DO - 10.1016/j.ejphar.2004.09.062
M3 - Article
C2 - 15588737
AN - SCOPUS:9944228231
SN - 0014-2999
VL - 506
SP - 165
EP - 168
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 2
ER -